GPRC5D CAR-T FOR MULTIPLE MYELOMA
โ WHAT PATIENTS NEED TO KNOW
Prepared by the CancerFax oncology navigation team. Updated regularly based on treatment access and clinical availability.
Why GPRC5D CAR-T Matters for Multiple Myeloma
BCMA (B-cell maturation antigen) has been the dominant target in modern myeloma immunotherapy. BCMA-directed CAR-T products, BCMA bispecific antibodies, and BCMA antibody-drug conjugates have all produced meaningful responses in patients who have exhausted standard regimens. This has been one of the most important advances in myeloma in the past decade. But long-term follow-up has revealed a familiar pattern. Many patients eventually relapse after BCMA-directed therapy, and one of the leading causes of relapse is loss or downregulation of BCMA on the myeloma cells. The cancer effectively hides by removing the antigen the therapy was trained to attack. When this happens, repeating BCMA-directed therapy is often ineffective, and patients need a different target. GPRC5D is one of the most promising alternatives. It is expressed on most myeloma cells and on a few normal tissues, primarily hair follicles, taste buds, and parts of the tongue. It is not normally found on essential organs, which makes it an attractive CAR-T target. Importantly, GPRC5D expression is largely independent of BCMA, so myeloma cells that have lost BCMA usually still express GPRC5D and remain vulnerable to GPRC5D-directed therapy. Chinese investigators have led much of the published clinical work on GPRC5D CAR-T, including monotherapy products and dual-target BCMA-GPRC5D constructs designed to attack both antigens at once. Several Chinese academic centres run active trials in heavily pre-treated patients, including those who have already failed BCMA CAR-T.
How GPRC5D CAR-T Works
The therapy follows the same overall pathway as standard CAR-T cell therapy, with the engineering directed at GPRC5D rather than BCMA or CD19: Step 1 โ T Cell Collection The patient's T cells are collected through leukapheresis, similar to the start of any autologous CAR-T pathway. Some platforms use donor cells or off-the-shelf platforms, particularly when the patient's own T cells are exhausted from prior therapy. Step 2 โ Engineering T cells are engineered to express a chimeric antigen receptor that recognises GPRC5D on the surface of myeloma cells. Several design strategies are in clinical use, including standard single-target GPRC5D CAR-T, tandem CAR with both BCMA and GPRC5D recognition domains, dual CAR with two separate receptors expressed on the same cell, and cocktail or sequential infusion of two distinct CAR-T products. Step 3 โ Lymphodepletion and Infusion The patient receives lymphodepleting chemotherapy, usually fludarabine and cyclophosphamide, followed by infusion of the engineered cells. Monitoring follows the same approach as other CAR-T therapies, with attention to cytokine release syndrome, neurotoxicity, prolonged cytopenias, and infections. Step 4 โ Disease Response Engineered cells expand in the body, recognise GPRC5D on myeloma cells, and destroy them. Response is tracked using standard myeloma criteria, including serum and urine protein electrophoresis, free light chains, bone marrow assessment, imaging of any extramedullary disease, and minimal residual disease (MRD) testing where appropriate.
Who May Be Suitable
Eligibility is always reviewed by the treating hospital and depends on multiple factors:
Confirmed pathology of multiple myeloma with current disease
Confirmed pathology of multiple myeloma with current disease activity, including measurable paraprotein, free light chains, plasmacytoma, or bone marrow involvement
GPRC5D expression confirmed on flow cytometry or IHC of rece
GPRC5D expression confirmed on flow cytometry or IHC of recent bone marrow or biopsy material, since trials usually require demonstrable target expression
Relapsed or refractory disease, typically after at least thr
Relapsed or refractory disease, typically after at least three prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody (so-called triple-class exposed disease)
Prior BCMA-directed therapy is increasingly common at the po
Prior BCMA-directed therapy is increasingly common at the point of GPRC5D CAR-T consideration; documented BCMA loss on relapse biopsy supports the case for switching target
No clinically significant CNS involvement, or treated and st
No clinically significant CNS involvement, or treated and stable CNS disease in selected protocols
Adequate organ function โ heart, liver, kidney, lung โ with
Adequate organ function โ heart, liver, kidney, lung โ with attention to renal function which is often impaired in myeloma
Acceptable blood counts and bone marrow reserve for lymphode
Acceptable blood counts and bone marrow reserve for lymphodepletion and post-CAR-T cytopenia management
ECOG performance status, typically 0 to 2, depending on prot
ECOG performance status, typically 0 to 2, depending on protocol
No active uncontrolled infection, including hepatitis B, hep
No active uncontrolled infection, including hepatitis B, hepatitis C, or HIV outside protocol allowances
Sufficient T-cell counts for manufacturing and ability to to
Sufficient T-cell counts for manufacturing and ability to tolerate lymphodepleting chemotherapy
Travel fitness and a realistic plan for several weeks of in-
Travel fitness and a realistic plan for several weeks of in-country care, including bridging therapy if disease is progressing during the manufacturing window
Side Effects Specific to GPRC5D CAR-T
GPRC5D CAR-T shares the general side effect profile of other CAR-T therapies, including cytokine release syndrome, neurotoxicity (ICANS), prolonged cytopenias, and infection risk. Because GPRC5D is also expressed on hair follicles, taste buds, and parts of the tongue, GPRC5D-directed therapy has a few additional on-target off-tumour effects worth knowing about: These effects are usually mild to moderate and reversible as the CAR-T cells decline over time. They are distinct from the toxicities associated with BCMA CAR-T or chemotherapy and are part of how GPRC5D CAR-T behaves. Most patients consider these effects acceptable in the context of treating advanced refractory myeloma, but they should be discussed openly with the treating team before infusion. Cytokine release syndrome, neurotoxicity, infection, and prolonged cytopenias are managed using the same approaches as in other CAR-T therapies, including tocilizumab, steroids, antibiotics, growth factors, and supportive care.
Changes in taste, ranging from mild altered taste to tempora
Changes in taste, ranging from mild altered taste to temporary loss of taste, sometimes lasting weeks
Dry mouth and changes in tongue surface, occasionally with d
Dry mouth and changes in tongue surface, occasionally with discomfort or difficulty eating spicy food
Hair changes, including thinning or temporary changes in hai
Hair changes, including thinning or temporary changes in hair texture or growth
Nail changes in some patients
Nail changes in some patients
How GPRC5D CAR-T Compares with BCMA CAR-T in Multiple Myeloma
This comparison is general. Many patients with relapsed myeloma are now considered for a sequence of cellular therapies โ for example, BCMA CAR-T followed later by GPRC5D CAR-T, or upfront dual-target BCMA-GPRC5D CAR-T โ rather than choosing between them. The treating haematology team makes the final decision based on prior treatment, antigen expression, fitness, and trial availability.
Where This May Be Available
GPRC5D CAR-T trials are currently most active in China, where multiple academic and specialist haematology centres run dedicated programmes in monotherapy GPRC5D CAR-T and in dual-target BCMA-GPRC5D constructs. Strong programmes operate at the Chinese Academy of Medical Sciences and National Cancer Center, Fudan University Shanghai Cancer Center, Renji Hospital, Ruijin Hospital, Peking University Cancer Hospital, Sun Yat-sen University Cancer Center, and several university-affiliated cell therapy units in Beijing, Shanghai, Guangzhou, Tianjin, and other cities. Selected trials are also active in the United States and Europe, although the volume and variety of GPRC5D-directed protocols are smaller. GPRC5D CAR-T is concentrated in specialised cell therapy centres rather than every cancer hospital, because the science is newer and the manufacturing more complex. The right centre for a given case depends on diagnosis, antigen expression, prior therapy history, and trial availability rather than hospital name alone. CancerFax helps match the case with a centre that fits the clinical situation.
Frequently Asked Questions
Answers to common questions from patients and families.
Why target GPRC5D instead of BCMA?
BCMA-directed CAR-T is highly effective in many patients, but a major reason it eventually fails is that the myeloma cells lose or reduce BCMA expression. By targeting GPRC5D, which is expressed on most myeloma cells regardless of BCMA status, GPRC5D-directed therapy gives a meaningful option to patients who have already exhausted BCMA-directed approaches. Some platforms target both antigens at once for the same reason.
Can I receive GPRC5D CAR-T after BCMA CAR-T?
In many cases, yes, particularly if recent biopsy shows that GPRC5D is still expressed on the myeloma cells and the patient is otherwise fit for cell therapy. This is one of the main settings where GPRC5D CAR-T is being studied. Eligibility depends on the time since previous CAR-T, current disease status, antigen expression, and overall fitness.
Is GPRC5D CAR-T approved?
In most countries, including China, GPRC5D CAR-T is still investigational and is delivered through clinical trials and specialist hospital programmes rather than as a fully approved commercial product. China has the most active clinical pipeline globally. There is also a GPRC5D-directed bispecific antibody, talquetamab, which has been approved in some markets and is conceptually related but mechanistically different from CAR-T.
Why does GPRC5D CAR-T affect taste and hair?
GPRC5D is also expressed on hair follicles, nail tissue, taste buds, and parts of the tongue. CAR-T cells engineered against GPRC5D recognise these tissues as well as the cancer, leading to changes in taste, dry mouth, hair, and occasionally nails. These effects are usually mild to moderate and reversible as the CAR-T cells decline over time. They are part of how the therapy works rather than a manufacturing problem.
How does GPRC5D CAR-T compare with talquetamab?
Both target GPRC5D, but they are different types of therapy. Talquetamab is a bispecific antibody that brings T cells to GPRC5D-positive myeloma cells and is given as repeated subcutaneous or intravenous doses over months. CAR-T is a one-time infusion of engineered cells after lymphodepletion. They are complementary tools rather than identical. Some patients may receive talquetamab in earlier lines and CAR-T in later lines, or vice versa, depending on availability.
Can international patients join GPRC5D CAR-T trials in China?
Yes, in many cases. Several Chinese hospitals accept international patients into GPRC5D CAR-T programmes and selected related trials, subject to full medical review, eligibility under the protocol, and visa arrangements. Because these protocols are concentrated in a smaller number of specialist centres, advance review of pathology, antigen expression, and treatment history is especially important. CancerFax helps assemble the medical record and confirms whether a specific protocol is open before travel is planned.
How long do responses last?
Long-term durability data are still maturing. Published Chinese series have shown meaningful response rates and progression-free intervals in heavily pre-treated patients, including some who had failed BCMA-directed therapy. Responses are not always permanent, and many patients ultimately need further therapy. Cellular therapy in advanced myeloma is generally about achieving deep responses and meaningful disease control, often as part of a longer treatment sequence.
How much does GPRC5D CAR-T cost in China?
Cost depends on the specific protocol, hospital, whether access is approved-use or trial-based, and the patient's condition at admission. Trial-based access can reduce drug cost significantly. Beyond the cell therapy itself, families should plan for hospital charges, lymphodepletion, monitoring, accommodation, interpreter support, possible bridging therapy, IVIG support after discharge, and any subsequent therapy. CancerFax helps patients understand realistic ranges before travel; final cost is confirmed by the hospital after review.
Reference Data
Structured reference data summarizing key information for this topic.
| Question | BCMA CAR-T | GPRC5D CAR-T |
|---|---|---|
| Target antigen | BCMA on myeloma cells | GPRC5D on myeloma cells |
| Approval status globally | Approved products in many countries (e.g. ide-cel, cilta-cel) | Largely clinical-trial-stage globally; most active in China |
| Typical setting | Triple-class exposed relapsed/refractory myeloma | Often after BCMA-directed therapy failure, or as part of dual-target trials |
| On-target side effects | Hypogammaglobulinemia, infection risk, neurotoxicity | Taste changes, hair and nail changes, dry mouth, plus general CAR-T effects |
| Antigen escape concern | BCMA loss is a recognised cause of relapse | Less is known long-term; dual-target designs aim to reduce escape |
| Stay duration in China | Around six to ten weeks | Around six to ten weeks |
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Understanding Your Options?
If you or a family member has multiple myeloma that has progressed after multiple lines of therapy, especially after BCMA-directed CAR-T or BCMA bispecific antibodies, CancerFax can help organise the medical records, review pathology and antigen expression reports, and connect the case with suitable Chinese centres or clinical trial teams running GPRC5D and dual-target cellular therapy programmes.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.